Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Disitamab Vedotin Plus Toripalimab for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

NCT07151560 is registered in ClinicalTrials.gov with Renmin Hospital of Wuhan University as lead sponsor.

NCT NCT07151560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Disitamab Vedotin Plus Toripalimab for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Lead sponsor
Renmin Hospital of Wuhan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 30, 2025
Completion date
August 30, 2030
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

urology